BioDelivery Sciences

Latest Headlines

Latest Headlines

Quintiles signs on to help BioDelivery get its anti-addiction drug out the door

Raleigh, NC's BioDelivery Sciences is expecting to win FDA approval for its opioid-dependence patch this summer, and the biotech has enlisted global contractor Quintiles to handle the launch.

BioDelivery looks for $60M offering to boost addiction film, pain gel

BioDelivery Sciences is looking at a possible $60 million boost to programs in its lineup including the launch of its opioid dependence film Bunavail and continue on the approval path for its pain gel for diabetic neuropathy.

BioDelivery eyes $60M to get its anti-opioid gel through the FDA

Raleigh, NC's BioDelivery Sciences has signed a deal to trade 7.5 million shares for $60 million, planning to spend the lion's share of the proceeds to launch Bunavail, a gel designed to treat opioid dependence.

BDSI hauls in $20M for pain film, addiction gel

North Carolina's BioDelivery Sciences International locked down $20 million in debt financing, cash the company will use to develop two treatments with proprietary drug delivery methods.

BioDelivery Sciences snags rights to topical gel for diabetes pain

BioDelivery Sciences secured rights from Arcion Therapeutics to commercialize the company's first-of-its-kind topical gel to treat painful diabetic neuropathy.

BioDelivery snaps up mid-stage diabetic pain drug in potential $39.5M-plus pact

BioDelivery Sciences has added to its pipeline of treatments for the pain market, seizing worldwide rights to an experimental topical therapy for painful diabetic neuropathy (PDN) from Arcion Therapeutics.

BioDelivery garners $40M raise for late-stage pain program

Raleigh, NC-based BioDelivery Sciences International has pieced together a $40 million raise from investors, providing the cash needed to wrap a critical late-stage pain therapy program on its way to a planned date with the FDA.

BDSI's addiction oral patch approaches the market

Based on positive results of a pharmacokinetic study, BioDelivery Sciences is planning a second-quarter 2013 submission for marketing approval of its BioErodible MucoAdhesive (BEMA) formulation of buprenorphine and naloxone for the treatment of opioid dependence.

BDSI snags $2.5M milestone from Meda

BioDelivery Sciences International is in line for $2.5 million milestone payment from Meda, as Breakyl got its first regulatory clearance in the E.U.

BDSI gets patent for anti-opioid film

BioDelivery Sciences International has secured a patent for its dissolvable opioid-dependence treatment, and the company is looking to get BEMA Buprenorphine on the market as soon as next year.